🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07717385
Recruiting Not applicable

Sleep More, Stress Less: 90-Day Trial of Neuralli Mood

NCT07717385 · tracked via the Priya Life Science USA tracker
Sponsor
Efforia, Inc
Phase
Not applicable
Started
2026-06-30
Last updated
2026-07-21

Condition(s) studied

Psychological StressSleep DisturbanceAnxiety SymptomsDepressive SymptomsOccupational Burnout

Investigational drug(s) / intervention(s)

Neuralli Mood

Neuralli Mood: Two acid-resistant capsules taken once daily for 90 days. Each daily dose contains 30 billion CFU of L. plantarum PS128 and 20 billion heat-treated cells of L. paracasei PS23. Other ingredients include microcrystalline cellulose, hypromellose, pectin, glycerol, silica, and magnesium stearate.

Study summary

This decentralized, single-arm study evaluates the effects of 90 days of daily Neuralli Mood supplementation on perceived stress, sleep disturbance, mood, anxiety, depressive symptoms, happiness, and occupational burnout in adults experiencing stress or occasional sleep disruption. Participants serve as their own controls, completing validated self-report measures before beginning supplementation and again after the 90-day intervention, with safety and adherence check-ins during the study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: * Age 18 years or older and able to provide informed consent. * Generally healthy adult experiencing stress, occasional sleep disruption, low mood, anxiety symptoms, or work-related burnout. * Willing and able to take two capsules of Neuralli Mood daily for 90 days. * Willing and able to complete electronic baseline, follow-up, adherence, and safety assessments. * Has reliable access to the internet and an email-enabled device. Exclusion Criteria: * Pregnant or nursing. * Known allergy or hypersensitivity to Neuralli Mood, probiotics, or any product ingredient. * Severe or unstable gastrointestinal disease, including a condition for which probiotic use may be inappropriate. * Immunocompromised status or current immunosuppressive therapy. * Severe or unstable mood disorder, acute psychiatric symptoms, or a current risk of harm to self or others. * A clinically significant sleep disorder for which participation or changes in symptoms should be managed by a healthcare professional. * Cognitive impairment or another condition that prevents informed consent or reliable completion of study procedures. * History of a severe allergic reaction when the investigator determines probiotic use may present an unacceptable risk. * Use of a medication or presence of a medical condition for which a healthcare professional advises against probiotic supplementation. * Any other circumstance that, in the investigator's judgment, makes participation inappropriate or unsafe.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Efforia - Decentralized United States Study New York New York Recruiting

More Efforia, Inc trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07717385 on ClinicalTrials.gov ↗ ← All trials in the USA